Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Cornelis H.C. Dejong is active.

Publication


Featured researches published by Cornelis H.C. Dejong.


The New England Journal of Medicine | 2010

A Step-up Approach or Open Necrosectomy for Necrotizing Pancreatitis

Hjalmar C. van Santvoort; Marc G. Besselink; Olaf J. Bakker; H. Sijbrand Hofker; Marja A. Boermeester; Cornelis H.C. Dejong; Harry van Goor; Alexander F. Schaapherder; Casper H.J. van Eijck; Thomas L. Bollen; Bert van Ramshorst; Vincent B. Nieuwenhuijs; Robin Timmer; Johan S. Laméris; Philip M Kruyt; Eric R. Manusama; Erwin van der Harst; George P. van der Schelling; Tom M. Karsten; Eric J. Hesselink; Cornelis J. H. M. van Laarhoven; Camiel Rosman; K. Bosscha; Ralph J. de Wit; Alexander P. J. Houdijk; Maarten S. van Leeuwen; Erik Buskens; Hein G. Gooszen; Abstr Act

BACKGROUND Necrotizing pancreatitis with infected necrotic tissue is associated with a high rate of complications and death. Standard treatment is open necrosectomy. The outcome may be improved by a minimally invasive step-up approach. METHODS In this multicenter study, we randomly assigned 88 patients with necrotizing pancreatitis and suspected or confirmed infected necrotic tissue to undergo primary open necrosectomy or a step-up approach to treatment. The step-up approach consisted of percutaneous drainage followed, if necessary, by minimally invasive retroperitoneal necrosectomy. The primary end point was a composite of major complications (new-onset multiple-organ failure or multiple systemic complications, perforation of a visceral organ or enterocutaneous fistula, or bleeding) or death. RESULTS The primary end point occurred in 31 of 45 patients (69%) assigned to open necrosectomy and in 17 of 43 patients (40%) assigned to the step-up approach (risk ratio with the step-up approach, 0.57; 95% confidence interval, 0.38 to 0.87; P=0.006). Of the patients assigned to the step-up approach, 35% were treated with percutaneous drainage only. New-onset multiple-organ failure occurred less often in patients assigned to the step-up approach than in those assigned to open necrosectomy (12% vs. 40%, P=0.002). The rate of death did not differ significantly between groups (19% vs. 16%, P=0.70). Patients assigned to the step-up approach had a lower rate of incisional hernias (7% vs. 24%, P=0.03) and new-onset diabetes (16% vs. 38%, P=0.02). CONCLUSIONS A minimally invasive step-up approach, as compared with open necrosectomy, reduced the rate of the composite end point of major complications or death among patients with necrotizing pancreatitis and infected necrotic tissue. (Current Controlled Trials number, ISRCTN13975868.)


Archives of Surgery | 2009

Consensus Review of Optimal Perioperative Care in Colorectal Surgery: Enhanced Recovery After Surgery (ERAS) Group Recommendations

Kristoffer Lassen; Mattias Soop; Jonas Nygren; P. Boris W. Cox; Paul O. Hendry; Claudia Spies; Maarten F. von Meyenfeldt; Kenneth Fearon; Arthur Revhaug; Stig Norderval; Olle Ljungqvist; Dileep N. Lobo; Cornelis H.C. Dejong

OBJECTIVES To describe a consensus review of optimal perioperative care in colorectal surgery and to provide consensus recommendations for each item of an evidence-based protocol for optimal perioperative care. DATA SOURCES For every item of the perioperative treatment pathway, available English-language literature has been examined. STUDY SELECTION Particular attention was paid to meta-analyses, randomized controlled trials, and systematic reviews. DATA EXTRACTION A consensus recommendation for each protocol item was reached after critical appraisal of the literature by the group. DATA SYNTHESIS For most protocol items, recommendations are based on good-quality trials or meta-analyses of such trials. CONCLUSIONS The Enhanced Recovery After Surgery (ERAS) Group presents a comprehensive evidence-based consensus review of perioperative care for colorectal surgery. It is based on the evidence available for each element of the multimodal perioperative care pathway.


Clinical Nutrition | 2006

ESPEN Guidelines on Parenteral Nutrition: Pancreas

Luca Gianotti; R Meier; Dileep N. Lobo; Claudio Bassi; Cornelis H.C. Dejong; Johann Ockenga; Øivind Irtun; John MacFie

Assessment of the severity of acute pancreatitis (AP), together with the patients nutritional status is crucial in the decision making process that determines the need for artificial nutrition. Both should be done on admission and at frequent intervals thereafter. The indication for nutritional support in AP is actual or anticipated inadequate oral intake for 5-7 days. This period may be shorter in those with pre-existing malnutrition. Substrate metabolism in severe AP is similar to that in severe sepsis or trauma. Parenteral amino acids, glucose and lipid infusion do not affect pancreatic secretion and function. If lipids are administered, serum triglycerides must be monitored regularly. The use of intravenous lipids as part of parenteral nutrition (PN) is safe and feasible when hypertriglyceridemia is avoided. PN is indicated only in those patients who are unable to tolerate targeted requirements by the enteral route. As rates of EN tolerance increase then volumes of PN should be decreased. When PN is administered, particular attention should be given to avoid overfeeding. When PN is indicated, a parenteral glutamine supplementation should be considered. In chronic pancreatitis PN may, on rare occasions, be indicated in patients with gastric outlet obstruction secondary to duodenal stenosis or those with complex fistulation, and in occasional malnourished patients prior to surgery.


Gastroenterology | 2011

A Conservative and Minimally Invasive Approach to Necrotizing Pancreatitis Improves Outcome

Hjalmar C. van Santvoort; Olaf J. Bakker; Thomas L. Bollen; Marc G. Besselink; Usama Ahmed Ali; A. Marjolein Schrijver; Marja A. Boermeester; Harry van Goor; Cornelis H.C. Dejong; Casper H.J. van Eijck; Bert van Ramshorst; Alexander F. Schaapherder; Erwin van der Harst; Sijbrand Hofker; Vincent B. Nieuwenhuijs; Menno A. Brink; Philip M Kruyt; Eric R. Manusama; George P. van der Schelling; Tom M. Karsten; Eric J. Hesselink; Cornelis J. H. M. van Laarhoven; Camiel Rosman; K. Bosscha; Ralph J. de Wit; Alexander P. J. Houdijk; Miguel A. Cuesta; Peter J. Wahab; Hein G. Gooszen

BACKGROUND & AIMS Treatment of patients with necrotizing pancreatitis has become more conservative and less invasive, but there are few data from prospective studies to support the efficacy of this change. We performed a prospective multicenter study of treatment outcomes among patients with necrotizing pancreatitis. METHODS We collected data from 639 consecutive patients with necrotizing pancreatitis, from 2004 to 2008, treated at 21 Dutch hospitals. Data were analyzed for disease severity, interventions (radiologic, endoscopic, surgical), and outcome. RESULTS Overall mortality was 15% (n=93). Organ failure occurred in 240 patients (38%), with 35% mortality. Treatment was conservative in 397 patients (62%), with 7% mortality. An intervention was performed in 242 patients (38%), with 27% mortality; this included early emergency laparotomy in 32 patients (5%), with 78% mortality. Patients with longer times between admission and intervention had lower mortality: 0 to 14 days, 56%; 14 to 29 days, 26%; and >29 days, 15% (P<.001). A total of 208 patients (33%) received interventions for infected necrosis, with 19% mortality. Catheter drainage was most often performed as the first intervention (63% of cases), without additional necrosectomy in 35% of patients. Primary catheter drainage had fewer complications than primary necrosectomy (42% vs 64%, P=.003). Patients with pancreatic parenchymal necrosis (n=324), compared with patients with only peripancreatic necrosis (n=315), had a higher risk of organ failure (50% vs 24%, P<.001) and mortality (20% vs 9%, P<.001). CONCLUSIONS Approximately 62% of patients with necrotizing pancreatitis can be treated without an intervention and with low mortality. In patients with infected necrosis, delayed intervention and catheter drainage as first treatment improves outcome.


Liver International | 2008

Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment

Maartje A. J. van den Broek; Steven W.M. Olde Damink; Cornelis H.C. Dejong; Hauke Lang; M. Malagó; Rajiv Jalan; Fuat H. Saner

Liver failure is a dreaded and often fatal complication that sometimes follows a partial hepatic resection. This article reviews the definition, incidence, pathogenesis, risk factors, risk assessment, prevention, clinical features and treatment of post‐resectional liver failure (PLF). A systematic, computerized search was performed using key words related to ‘partial hepatic resection’ and ‘liver failure’ to review most relevant literature about PLF published in the last 20 years.


Hpb | 2010

Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases

Jan H.M.B. Stoot; Robert J.S. Coelen; Mechteld C. de Jong; Cornelis H.C. Dejong

BACKGROUND Malignant transformation of hepatocellular adenomas (HCAs) into hepatocellular carcinomas (HCCs) has been reported repeatedly and is considered to be one of the main reasons for surgical treatment. However, its actual risk is currently unknown. OBJECTIVE To provide an estimation of the frequency of malignant transformation of HCAs and to discuss its clinical implications. METHODS A systematic literature search was conducted using the following databases: The Cochrane Hepatobiliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, MEDLINE and EMBASE. RESULTS One hundred and fifty-seven relevant series and 17 case reports (a total of 1635 HCAs) were retrieved, reporting an overall frequency of malignant transformation of 4.2%. Only three cases (4.4%) of malignant alteration were reported in a tumour smaller than 5 cm in diameter. DISCUSSION Malignant transformation of HCAs into HCCs remains a rare phenomenon with a reported frequency of 4.2%. A better selection of exactly those patients presenting with an HCA with an amplified risk of malignant degeneration is advocated in order to reduce the number of liver resections and thus reducing the operative risk for these predominantly young patients. The Bordeaux adenoma tumour markers are a promising method of identifying these high-risk adenomas.


British Journal of Surgery | 2012

Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality

R.F. de Wilde; M.G. Besselink; I van der Tweel; I. H. J. T. de Hingh; C.H.J. van Eijck; Cornelis H.C. Dejong; Robert J. Porte; D. J. Gouma; O.R.C. Busch; I.Q. Molenaar

The impact of nationwide centralization of pancreaticoduodenectomy (PD) on mortality is largely unknown. The aim of this study was to analyse changes in hospital volumes and in‐hospital mortality after PD in the Netherlands between 2004 and 2009.


World Journal of Surgery | 2013

Guidelines for Perioperative Care for Pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS(®)) Society Recommendations.

Kristoffer Lassen; M.M.E. Coolsen; Karem Slim; Francesco Carli; José Eduardo de Aguilar-Nascimento; Markus Schäfer; Rowan W. Parks; Kenneth Fearon; Dileep N. Lobo; Nicolas Demartines; Marco Braga; Olle Ljungqvist; Cornelis H.C. Dejong

BackgroundProtocols for enhanced recovery provide comprehensive and evidence-based guidelines for best perioperative care. Protocol implementation may reduce complication rates and enhance functional recovery and, as a result of this, also reduce length-of-stay in hospital. There is no comprehensive framework available for pancreaticoduodenectomy.MethodsAn international working group constructed within the Enhanced Recovery After Surgery (ERAS®) Society constructed a comprehensive and evidence-based framework for best perioperative care for pancreaticoduodenectomy patients. Data were retrieved from standard databases and personal archives. Evidence and recommendations were classified according to the GRADE system and reached through consensus in the group. The quality of evidence was rated “high”, “moderate”, “low” or “very low”. Recommendations were graded as “strong” or “weak”.ResultsComprehensive guidelines are presented. Available evidence is summarised and recommendations given for 27 care items. The quality of evidence varies substantially and further research is needed for many issues to improve the strength of evidence and grade of recommendations.ConclusionsThe present evidence-based guidelines provide the necessary platform upon which to base a unified protocol for perioperative care for pancreaticoduodenectomy. A unified protocol allows for comparison between centres and across national borders. It facilitates multi-institutional prospective cohort registries and adequately powered randomised trials.


British Journal of Surgery | 2008

Initial experience with a multimodal enhanced recovery programme in patients undergoing liver resection

R.M. van Dam; Paul O. Hendry; M. M. E. Coolsen; Marc H.A. Bemelmans; Kristoffer Lassen; Arthur Revhaug; Kenneth Fearon; O. J. Garden; Cornelis H.C. Dejong

Accelerated recovery from surgery has been achieved when patients are managed within a multimodal Enhanced Recovery After Surgery (ERAS) protocol. This study evaluated the benefit of an ERAS programme for patients undergoing liver resection.


Critical Care Medicine | 2004

Sepsis: an arginine deficiency state?

Yvette C. Luiking; Martijn Poeze; Cornelis H.C. Dejong; Graham Ramsay; Nicolaas E. P. Deutz

Objective:Sepsis is a major health problem considering its significant morbidity and mortality rate. The amino acid l-arginine has recently received substantial attention in relation to human sepsis. However, knowledge of arginine metabolism during sepsis is limited. Therefore, we reviewed the current knowledge about arginine metabolism in sepsis. Data Source:This review summarizes the literature on arginine metabolism both in general and in relation to sepsis. Moreover, arginine-related therapies are reviewed and discussed, which includes therapies of both nitric oxide (NO) and arginine administration and therapies directed toward inhibition of NO. Data:In sepsis, protein breakdown is increased, which is a key process to maintain arginine delivery, because both endogenous de novo production from citrulline and food intake are reduced. Arginine catabolism, on the other hand, is markedly increased by enhanced use of arginine in the arginase and NO pathways. As a result, lowered plasma arginine levels are usually found. Clinical symptoms of sepsis that are related to changes in arginine metabolism are mainly related to hemodynamic alterations and diminished microcirculation. NO administration and arginine supplementation as a monotherapy demonstrated beneficial effects, whereas nonselective NO synthase inhibition seemed not to be beneficial, and selective NO synthase 2 inhibition was not beneficial overall. Conclusions:Because sepsis has all the characteristics of an arginine-deficiency state, we hypothesise that arginine supplementation is a logical option in the treatment of sepsis. This is supported by substantial experimental and clinical data on NO donors and NO inhibitors. However, further evidence is required to prove our hypothesis.

Collaboration


Dive into the Cornelis H.C. Dejong's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kaatje Lenaerts

Maastricht University Medical Centre

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge